Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/36047
Campo DC Valoridioma
dc.contributor.authorRodríguez, Marioen_US
dc.contributor.authorMárquez, Saioaen_US
dc.contributor.authorDe La Rosa Medina, Vladimiren_US
dc.contributor.authorAlonso, Saraen_US
dc.contributor.authorCastrillo Viguera, Antonioen_US
dc.contributor.authorSánchez Crespo, Marianoen_US
dc.contributor.authorFernández, Nievesen_US
dc.date.accessioned2018-05-11T12:25:30Z-
dc.date.available2018-05-11T12:25:30Z-
dc.date.issued2017en_US
dc.identifier.issn0019-2805en_US
dc.identifier.urihttp://hdl.handle.net/10553/36047-
dc.description.abstractCyclic AMP regulatory element binding protein and signal transducer and activator of transcription 3 (STAT3) may control inflammation by several mechanisms, one of the best characterized is the induction of the expression of the anti-inflammatory cytokine interleukin-10 (IL-10). STAT3 also down-regulates the production of pro-inflammatory cytokines induced by immunoreceptor tyrosine-based activation motif (ITAM)-coupled receptors, a mechanism termed cross-inhibition. Because signalling via ITAM-dependent mechanisms is a hallmark of fungal pattern receptors, STAT3 activation might be involved in the cross-inhibition associated with invasive fungal infections. The fungal surrogate zymosan produced the phosphorylation of Y705-STAT3 and the expression of Ifnb1 and Socs3, but did not induce the interferon (IFN)-signature cytokines Cxcl9 and Cxcl10 in bone marrow-derived dendritic cells. Unlike lipopolysaccharide (LPS), zymosan induced IL-10 and phosphorylated Y705-STAT3 to a similar extent in Irf3 and Ifnar1 knockout and wild-type mice. Human dendritic cells showed similar results, although the induction of IFNB1 was less prominent. These results indicate that LPS and zymosan activate STAT3 through different routes. Whereas type I IFN is the main effector of LPS effect, the mechanism involved in Y705-STAT3 phosphorylation by zymosan is more complex, cannot be associated with type I IFN, IL-6 or granulocyte-macrophage colony-stimulating factor, and seems dependent on several factors given that it was partially inhibited by the platelet-activating factor antagonist WEB2086 and high concentrations of COX inhibitors, p38 mitogen-activate protein kinase inhibitors, and blockade of tumour necrosis factor-alpha function. Altogether, these results indicate that fungal pattern receptors share with other ITAM-coupled receptors the capacity to produce cross-inhibition through a mechanism involving STAT3 and induction of SOCS3 and IL-10, but that cannot be explained through type I IFN signalling.en_US
dc.languageengen_US
dc.relation.ispartofImmunologyen_US
dc.sourceImmunology [ISSN 0019-2805], v. 150 (2), p. 184-198en_US
dc.subject2412 Inmunologíaen_US
dc.subject32 Ciencias médicasen_US
dc.subject.otherCytokinesen_US
dc.subject.otherDendritic cellsen_US
dc.subject.otherFungal infectionen_US
dc.subject.otherInflammationen_US
dc.titleFungal pattern receptors down-regulate the inflammatory response by a cross-inhibitory mechanism independent of interleukin-10 productionen_US
dc.typeinfo:eu-repo/semantics/Articlees
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticlees
dc.identifier.doi10.1111/imm.12678
dc.identifier.scopus85002388948-
dc.identifier.isi000394790400007-
dc.contributor.authorscopusid56411145300
dc.contributor.authorscopusid57002865900
dc.contributor.authorscopusid55926663500
dc.contributor.authorscopusid7102615617
dc.contributor.authorscopusid55445301000
dc.contributor.authorscopusid35432052000
dc.contributor.authorscopusid7102523522
dc.identifier.eissn1365-2567-
dc.description.lastpage198-
dc.identifier.issue2-
dc.description.firstpage184-
dc.relation.volume150-
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.contributor.daisngid5287488
dc.contributor.daisngid10012329
dc.contributor.daisngid6668944
dc.contributor.daisngid9454061
dc.contributor.daisngid225640
dc.contributor.daisngid251681
dc.contributor.daisngid1807356
dc.contributor.wosstandardWOS:Rodriguez, M
dc.contributor.wosstandardWOS:Marquez, S
dc.contributor.wosstandardWOS:de la Rosa, JV
dc.contributor.wosstandardWOS:Alonso, S
dc.contributor.wosstandardWOS:Castrillo, A
dc.contributor.wosstandardWOS:Crespo, MS
dc.contributor.wosstandardWOS:Fernandez, N
dc.date.coverdateFebrero 2017
dc.identifier.ulpgces
dc.description.sjr1,69
dc.description.jcr3,358
dc.description.sjrqQ1
dc.description.jcrqQ2
dc.description.scieSCIE
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología-
crisitem.author.deptGIR IUIBS: Farmacología Molecular y Traslacional-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-1443-7548-
crisitem.author.orcid0000-0002-2057-2159-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameDe La Rosa Medina, Juan Vladimir-
crisitem.author.fullNameCastrillo Viguera, Antonio Jesús-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

10
actualizado el 01-dic-2024

Citas de WEB OF SCIENCETM
Citations

10
actualizado el 24-nov-2024

Visitas

49
actualizado el 27-jul-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.